Across TCGA pan-cancer cohorts, FSCN2 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of FSCN2’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FSCN2 RNA is repressed in tumor relative to normal tissue. In most cancer types FSCN2 is over-expressed in tumor, although a few such as KIRC and LUSC show the opposite, repressed pattern.
KIRC, COAD, and LIHC are the cancer types where FSCN2 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FSCN2 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.